Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

The emerging role of the molecular marker p27 in the differential diagnosis of adrenocortical tumors.

Pereira SS, Morais T, Costa MM, Monteiro MP, Pignatelli D.

Endocr Connect. 2013 Aug 28;2(3):137-45. doi: 10.1530/EC-13-0025. Print 2013.

2.

Expression of cell cycle inhibitor p27 and Ki-67 in human adrenocortical neoplasms.

Nakazumi H, Sasano H, Iino K, Ohashi Y, Orikasa S.

Mod Pathol. 1998 Dec;11(12):1165-70.

PMID:
9872646
3.

Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas.

Soon PS, Gill AJ, Benn DE, Clarkson A, Robinson BG, McDonald KL, Sidhu SB.

Endocr Relat Cancer. 2009 Jun;16(2):573-83. doi: 10.1677/ERC-08-0237. Epub 2009 Feb 13.

4.

Indicators of malignancy of canine adrenocortical tumors: histopathology and proliferation index.

Labelle P, Kyles AE, Farver TB, De Cock HE.

Vet Pathol. 2004 Sep;41(5):490-7.

PMID:
15347821
5.

Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors.

Erickson LA, Jin L, Wollan PC, Thompson GB, van Heerden J, Lloyd RV.

Mod Pathol. 1998 Feb;11(2):169-74.

PMID:
9504687
6.

Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis.

Stojadinovic A, Hoos A, Nissan A, Dudas ME, Cordon-Cardo C, Shaha AR, Brennan MF, Singh B, Ghossein RA.

Hum Pathol. 2003 Jan;34(1):54-64.

PMID:
12605367
7.

Weineke criteria, Ki-67 index and p53 status to study pediatric adrenocortical tumors: Is there a correlation?

Das S, Sengupta M, Islam N, Roy P, Datta C, Mishra PK, Banerjee S, Chaudhuri MK, Chatterjee U.

J Pediatr Surg. 2016 Nov;51(11):1795-1800. doi: 10.1016/j.jpedsurg.2016.07.014. Epub 2016 Aug 8.

PMID:
27567308
8.

Angiogenesis and Lymphangiogenesis in the Adrenocortical Tumors.

Pereira SS, Costa MM, Guerreiro SG, Monteiro MP, Pignatelli D.

Pathol Oncol Res. 2017 Jul 10. doi: 10.1007/s12253-017-0259-6. [Epub ahead of print]

PMID:
28695321
9.

DNA topoisomerase II alpha and Ki-67 in human adrenocortical neoplasms: a possible marker of differentiation between adenomas and carcinomas.

Iino K, Sasano H, Yabuki N, Oki Y, Kikuchi A, Yoshimi T, Nagura H.

Mod Pathol. 1997 Sep;10(9):901-7.

PMID:
9310953
10.

Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors.

Lidhar K, Korbonits M, Jordan S, Khalimova Z, Kaltsas G, Lu X, Clayton RN, Jenkins PJ, Monson JP, Besser GM, Lowe DG, Grossman AB.

J Clin Endocrinol Metab. 1999 Oct;84(10):3823-30.

PMID:
10523037
11.

Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors.

Terzolo M, Boccuzzi A, Bovio S, Cappia S, De Giuli P, Alì A, Paccotti P, Porpiglia F, Fontana D, Angeli A.

Urology. 2001 Jan;57(1):176-82.

PMID:
11164177
12.

Apoptosis control and proliferation marker in human normal and neoplastic adrenocortical tissues.

Bernini GP, Moretti A, Viacava P, Bonadio AG, Iacconi P, Miccoli P, Salvetti A.

Br J Cancer. 2002 May 20;86(10):1561-5.

13.

Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.

Strong VE, Kennedy T, Al-Ahmadie H, Tang L, Coleman J, Fong Y, Brennan M, Ghossein RA.

Surgery. 2008 Jun;143(6):759-68. doi: 10.1016/j.surg.2008.02.007. Epub 2008 Apr 14.

PMID:
18549892
14.

Chromatin texture analysis of cortical adrenal gland adenomas, including incidentalomas, and adjacent normal-appearing cortical tissue.

Scarpelli M, Baccarini MG, Colanzi P, Arnaldi G, Montironi R, Thompson D, Bartels PH.

Anal Quant Cytol Histol. 2000 Jun;22(3):235-43.

PMID:
10872041
15.

Differential expression of cyclin D1 in human pituitary tumors: relation to MIB-1 and p27/Kip1 labeling indices.

Hewedi IH, Osman WM, El Mahdy MM.

J Egypt Natl Canc Inst. 2011 Dec;23(4):171-9. doi: 10.1016/j.jnci.2011.11.003. Epub 2011 Dec 29.

16.

The role of immunohistochemistry in histopathological diagnostics of clinically "silent" incidentally detected adrenal masses.

Babinska A, Sworczak K, Wisniewski P, Nałecz A, Jaskiewicz K.

Exp Clin Endocrinol Diabetes. 2008 Apr;116(4):246-51. doi: 10.1055/s-2007-993164.

PMID:
18393131
17.

Defining a molecular phenotype for benign and malignant parathyroid tumors.

Fernandez-Ranvier GG, Khanafshar E, Tacha D, Wong M, Kebebew E, Duh QY, Clark OH.

Cancer. 2009 Jan 15;115(2):334-44. doi: 10.1002/cncr.24037.

18.

Analysis of histological and immunohistochemical patterns of benign and malignant adrenocortical tumors by computerized morphometry.

Dalino Ciaramella P, Vertemati M, Petrella D, Bonacina E, Grossrubatscher E, Duregon E, Volante M, Papotti M, Loli P.

Pathol Res Pract. 2017 Jul;213(7):815-823. doi: 10.1016/j.prp.2017.03.004. Epub 2017 Mar 9.

PMID:
28554744
19.

A hybrid machine learning-based method for classifying the Cushing's Syndrome with comorbid adrenocortical lesions.

Yang JY, Yang MQ, Luo Z, Ma Y, Li J, Deng Y, Huang X.

BMC Genomics. 2008;9 Suppl 1:S23. doi: 10.1186/1471-2164-9-S1-S23.

20.

Reduced serum levels of dehydroepiandrosterone sulphate in adrenal incidentalomas: a marker of adrenocortical tumour.

Flecchia D, Mazza E, Carlini M, Blatto A, Olivieri F, Serra G, Camanni F, Messina M.

Clin Endocrinol (Oxf). 1995 Feb;42(2):129-34.

PMID:
7704956

Supplemental Content

Support Center